Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICROGESTIN 1/20 vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing estrogen (ethinyl estradiol) and progestin (norethindrone acetate). Inhibits gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation. Also causes cervical mucus thickening and endometrial thinning.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females ≥15 years who have achieved menarche and are using oral contraception (FDA approved for this indication with 20 mcg ethinyl estradiol formulation)
Prevention of pregnancy
One tablet (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Norethindrone: 5.2-12.8 hours (mean ~8 hours); Ethinyl estradiol: 7-20 hours (mean ~13 hours); hepatic impairment prolongs.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Ethinyl estradiol metabolized primarily by CYP3A4 via hydroxylation; also conjugated with sulfate and glucuronic acid. Norethindrone acetate deacetylated to norethindrone, then metabolized by reduction and conjugation; CYP3A4 minor role.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: 40% as metabolites, 20% as glucuronide and sulfate conjugates; Fecal: 35%; Biliary: <5%.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Norethindrone: 60-80% bound to SHBG and albumin; Ethinyl estradiol: 95-98% bound to albumin.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Norethindrone: 3.4-5.5 L/kg; Ethinyl estradiol: 2.6-4.4 L/kg; reflects extensive tissue distribution.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: Norethindrone 64-70%; Ethinyl estradiol 38-48% (first-pass metabolism).
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No specific dose adjustment recommended; data limited. Use caution in patients with significant renal impairment due to potential fluid retention.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in severe hepatic disease (Child-Pugh C) due to impaired steroid metabolism. Use lowest effective dose in mild to moderate impairment (Child-Pugh A/B) with close monitoring.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) with monitoring for adverse effects.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use after menopause due to increased risk of thromboembolic events and cardiovascular complications.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism) from COC use. Risk increases with age (especially >35) and number of cigarettes smoked. Women >35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI) - discontinue if symptoms occur,Increased risk of myocardial infarction, especially in smokers ≥35,Elevated blood pressure - monitor periodic BP,Gallbladder disease risk,Hepatic neoplasia risk (benign/malignant) - discontinue if jaundice develops,May worsen diabetes, hyperlipidemia, or migraines,Women with history of depression should be monitored,Retinal thrombosis - discontinue if visual symptoms occur,Increased risk of pancreatitis in women with hypertriglyceridemia,Possible increase in breast cancer risk - individual risk/benefit assessment
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Hepatic adenoma or carcinoma (current or history),Jaundice or liver disease with impaired function (active),Hypersensitivity to any component,Age >35 and smokes
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food restrictions; however, grapefruit juice may increase estrogen levels and is best avoided. High-fat meals may delay absorption but not clinically significant.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Microgestin 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure has been associated with a small increase in risk of congenital anomalies, including cardiovascular and limb defects. Use in second and third trimesters may cause fetal harm, including female pseudohermaphroditism with high doses of progestins.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Small amounts of contraceptive steroids have been identified in breast milk, with an estimated M/P ratio of approximately 0.3 for ethinyl estradiol. Norethindrone acetate is also excreted. Use may reduce milk production and composition, especially with early postpartum use. Generally not recommended during breastfeeding due to potential effects on the infant.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Microgestin 1/20 is contraindicated in pregnancy and should be discontinued immediately if pregnancy is suspected. No dose adjustments are applicable as the drug is not used during pregnancy. Physiological changes in pregnancy may affect pharmacokinetics, but no established dosing recommendations exist due to contraindication.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Initiate on first day of menstrual period or first Sunday after onset; no need for back-up contraception if started within first 5 days. Missed pill protocols: if 1 pill missed, take as soon as remembered; if 2+ pills missed, take last missed pill, use back-up for 7 days. May reduce menstrual cramps and acne. Contraindicated in smokers over 35 and those with history of DVT or migraine with aura.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one tablet daily at the same time to maintain steady hormone levels.,If you miss a pill, refer to the package insert for instructions; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, which usually improve after 2-3 cycles.,This medication does not protect against HIV or other STDs; use condoms for protection.,Notify your provider if you experience severe abdominal pain, chest pain, shortness of breath, or vision changes.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICROGESTIN 1/20 vs ALYACEN 7/7/7, answered by our medical review team.
MICROGESTIN 1/20 is a Oral Contraceptive that works by Combination oral contraceptive containing estrogen (ethinyl estradiol) and progestin (norethindrone acetate). Inhibits gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation. Also causes cervical mucus thickening and endometrial thinning.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICROGESTIN 1/20 and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICROGESTIN 1/20 is: One tablet (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICROGESTIN 1/20 and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICROGESTIN 1/20 is classified as Category C. Microgestin 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure has been associated with a small increase in risk of congenital. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.